Form 4: Agios CLO Sells Shares After PSU Vesting

Agios Pharmaceuticals' Chief Legal Officer, James William Burns, sold 2,932 shares of common stock to cover tax obligations following the vesting of 6,000 performance share units.

Summary

• James William Burns, Chief Legal Officer of Agios Pharmaceuticals, Inc. (AGIO), reported transactions on December 30, 2025.
• Burns acquired 6,000 shares of common stock through the exercise/vesting of performance share units (PSUs) at a price of $0.
• Concurrently, Burns disposed of 2,932 shares of common stock at a price of $27.09 per share.
• The sale of shares was executed to cover tax withholding obligations related to the vesting of the performance share units.
• This transaction was conducted under a Rule 10b5-1(c) plan, established on March 1, 2023.
• Following these transactions, Burns beneficially owns 31,718 shares of common stock directly.
• The vesting of the PSUs was triggered by the achievement of a specified regulatory milestone on December 29, 2025, which resulted in 50% of the underlying shares vesting.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of PSUs due to a milestone achievement is positive, indicating progress. The subsequent sale for tax purposes is a routine event and not indicative of negative sentiment towards the company.

Positives

• Achievement of a specified regulatory milestone on December 29, 2025, leading to the vesting of 50% of performance share units, indicating progress in the company's pipeline.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned sale and not a discretionary decision based on new, non-public information.

Negatives

• Disposition of 2,932 shares of common stock by a key officer, even if for tax purposes, reduces their direct ownership in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale of shares by an officer is a routine event for tax purposes following equity compensation vesting and is unlikely to have a significant direct impact on shareholders, though it slightly reduces insider ownership. The achievement of a regulatory milestone could be seen as positive for the company's pipeline and future value.

Next Steps

• Vested shares will be delivered to the reporting person within three business days after December 29, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where an executive sold shares to cover tax obligations after performance share units vested due to a milestone achievement. Such transactions are typically pre-scheduled under Rule 10b5-1 plans and do not reflect a discretionary decision based on new material information about the company's prospects. Therefore, this filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, assuming the company's fundamentals remain consistent with prior assessments. The milestone achievement is a positive, but the tax-related sale is neutral.

Keywords

Agios Pharmaceuticals, AGIO, Form 4, Insider Trading, Stock Sale, Performance Share Units, PSU Vesting, Chief Legal Officer, James William Burns, Rule 10b5-1